Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Interest & Investment Income (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Interest & Investment Income data on record, last reported at $3.3 million in Q1 2026.

  • On a quarterly basis, Interest & Investment Income rose 19.91% to $3.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $10.4 million, a 12.71% decrease, with the full-year FY2025 number at $9.9 million, down 18.76% from a year prior.
  • Interest & Investment Income reached $3.3 million in Q1 2026 per FULC's latest filing, up from $2.4 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for FULC hit a ceiling of $3.5 million in Q2 2023 and a floor of $70000.0 in Q1 2022.
  • A 5-year average of $2.4 million and a median of $2.9 million in 2024 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: surged 4415.71% in 2023, then plummeted 34.02% in 2025.
  • Tracing FULC's Interest & Investment Income over 5 years: stood at $1.8 million in 2022, then skyrocketed by 76.06% to $3.2 million in 2023, then fell by 11.59% to $2.9 million in 2024, then dropped by 17.55% to $2.4 million in 2025, then surged by 39.68% to $3.3 million in 2026.
  • Business Quant data shows Interest & Investment Income for FULC at $3.3 million in Q1 2026, $2.4 million in Q4 2025, and $2.3 million in Q3 2025.